Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids

Forensic Science International

Volumn 246, Issue , 2015, Pages 98-103

  Karinen, Ritva ^a   Tuv, Silja Skogstad ^a   Øiestad, Elisabeth Leere ^a   Vindenes, Vigdis ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Autopsy cases; DUID cases; Intoxications; Pharmacokinetic studies; Synthetic cannabinoids

Indexed keywords

(1 PENTYL 1H INDOL 3 YL)(2,2,3,3 TETRAMETHYLCYCLOPROPYL)METHANONE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; AM 2201; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; DRUG METABOLITE; JWH 019; JWH 081; JWH 122; JWH 210; JWH 250; JWH 307; MAM 2201; N (1 ADAMANTYL) 1 (5 FLUOROPENTYL) 1H INDAZOLE 3 CARBOXAMIDE; N (1 ADAMANTYL) 1 PENTYL 1H INDAZOLE 3 CARBOXAMIDE; RSC 4; UNCLASSIFIED DRUG; XRL 11; (1-PENTYL-1H-INDOL-3-YL)(2,2,3,3-TETRAMETHYLCYCLOPROPYL)METHANONE; (4-METHYL-1-NAPHTHYL)-(1-PENTYLINDOL-3-YL)METHANONE; 1-(5-FLUOROPENTYL)-3-(4-METHYL-1-NAPHTHOYL)INDOLE; 1-PENTYL-3-(1-NAPHTHOYL)INDOLE; 4-ETHYLNAPHTHALEN-1-YL-(1-PENTYLINDOL-3-YL)METHANONE; CANNABINOID; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ARTICLE; AUTOPSY; BLOOD LEVEL; BLOOD SAMPLING; CAR DRIVING; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRIVER; DRIVING UNDER THE INFLUENCE OF DRUG; DRUG ABUSE; HUMAN; INCIDENCE; INTOXICATION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PLASMA CONCENTRATION-TIME CURVE; BLOOD; LEGISLATION AND JURISPRUDENCE; NORWAY; SUBSTANCE ABUSE;

AUTOMOBILE DRIVING; CANNABINOIDS; HUMANS; INDOLES; NAPHTHALENES; NORWAY; SUBSTANCE ABUSE DETECTION;

EID: 84914125340     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2014.11.012     Document Type: Article

References (44)

1. Lapoint J., James L.P., Moran C.L., Nelson L.S., Hoffman R.S., Moran J.H. Severe toxicity following synthetic cannabinoid ingestion. Clin. Toxicol. (Phila.) 2011, 49:760-764.
2. Simmons J., Cookman L., Kang C., Skinner C. Three cases of "spice" exposure. Clin. Toxicol. (Phila.) 2011, 49:431-433.
3. Simmons J.R., Skinner C.G., Williams J., Kang C.S., Schwartz M.D., Wills B.K. Intoxication from smoking "spice". Ann. Emerg. Med. 2011, 57:187-188.
4. Thornton S.L., Wood C., Friesen M.W., Gerona R.R. Synthetic cannabinoid use associated with acute kidney injury. Clin. Toxicol. (Phila.) 2013, 51:189-190.
5. Hoyte C.O., Jacob J., Monte A.A., Al-Jumaan M., Bronstein A.C., Heard K.J. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012, 60:435-438.
6. Kronstrand R., Roman M., Andersson M., Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J. Anal. Toxicol. 2013, 37:534-541.
7. Patton A.L., Chimalakonda K.C., Moran C.L., McCain K.R., Radominska-Pandya A., James L.P., Kokes C., Moran J.H. K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J. Forensic Sci. 2013, 58:1676-1680.
8. Shanks K.G., Dahn T., Terrell A.R. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J. Anal. Toxicol. 2012, 36:145-152.
9. Gandhi A.S., Zhu M., Pang S., Wohlfarth A., Scheidweiler K.B., Liu H.F., Huestis M.A. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013, 15:1091-1098.
10. Wohlfarth A., Gandhi A., Pang S., Zhu M., Scheidweiler K., Huestis M. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal. Bioanal. Chem. 2014, 406:1763-1780.
11. Wohlfarth A., Pang S., Zhu M., Gandhi A.S., Scheidweiler K.B., Liu H.F., Huestis M.A. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin. Chem. 2013, 59:1638-1648.
12. Gandhi A.S., Wohlfarth A., Zhu M., Pang S., Castaneto M., Scheidweiler K.B., Huestis M.A. High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test. Anal. 2014, 10.1002/dta.1662.
13. Gandhi A.S., Zhu M., Pang S., Wohlfarth A., Scheidweiler K.B., Huestis M.A. Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS. Bioanalysis 2014, 6:1471-1485.
14. Wohlfarth A., Pang S., Zhu M., Gandhi A.S., Scheidweiler K.B., Huestis M.A. Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 2014, 6:1187-1200.
15. Gambaro V., Arnoldi S., Bellucci S., Casagni E., Dell'Acqua L., Fumagalli L., Pallavicini M., Roda G., Rusconi C., Valoti E. Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids. J. Chromatogr. B 2014, 957:68-76.
16. Uchiyama N., Kawamura M., Kikura-Hanajiri R., Goda Y. Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol. 2012, 30:114-125.
17. Holm N.B., Pedersen A.J., Dalsgaard P.W., Linnet K. Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test. Anal. 2014.
18. Adamowicz P., Zuba D., Sekuła K. Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci. Int. 2013, 233:320-327.
19. Auwärter V., Dargan P.I., Wood D.M. Novel Psychoactive Substances 2013, Academic Press, Boston. P.I.D.M. Wood (Ed.).
20. Karinen R., Johnsen L., Andresen W., Christophersen A.S., Vindenes V., Øiestad E.L. Stability study of fifteen synthetic cannabinoids of aminoalkylindole type in whole blood, stored in Vacutainer® evacuated glass tubes. J. Forensic Toxicol. Pharmacol. 2013, 2(1).
21. Dziadosz M., Klintschar M., Teske J. Mixed consumption of cannabis and "Spice". Forensic Sci. Int. 2014, 235:e1-e2.
22. Musshoff F., Madea B., Kernbach-Wighton G., Bicker W., Kneisel S., Hutter M., Auwarter V. Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int. J. Legal Med. 2014, 128:59-64.
23. Lemos N.P. Driving under the influence of synthetic cannabinoid receptor agonist XLR-11. J. Forensic Sci. 2014.
24. Tuv S.S., Krabseth H., Karinen R., Olsen K.M., Oiestad E.L., Vindenes V. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid. Anal. Prev. 2014, 62:26-31.
25. Yeakel J.K., Logan B.K. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J. Anal. Toxicol. 2013, 37:547-551.
26. Castaneto M.S., Gorelick D.A., Desrosiers N.A., Hartman R.L., Pirard S., Huestis M.A. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014, 10.1016/j.drugalcdep.2014.08.005.
27. Derungs A., Schwaninger A., Mansella G., Bingisser R., Kraemer T., Liechti M. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol. 2013, 31:164-171.
28. Hermanns-Clausen M., Kneisel S., Hutter M., Szabo B., Auwarter V. Acute intoxication by synthetic cannabinoids - four case reports. Drug Test. Anal. 2013, 5:790-794.
29. Hermanns-Clausen M., Kneisel S., Szabo B., Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013, 108:534-544.
30. Lonati D., Buscaglia E., Papa P., Valli A., Coccini T., Giampreti A., Petrolini V.M., Vecchio S., Serpelloni G., Locatelli C.A. MAM-2201 (analytically confirmed) intoxication after "Synthacaine" consumption. Ann. Emerg. Med. 2014, 10.1016/j.annemergmed.2014.01.007.
31. Dresen S., Kneisel S., Weinmann W., Zimmermann R., Auwärter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J. Mass Spectrom. 2011, 46:163-171.
32. Kneisel S., Auwarter V. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J. Mass Spectrom. 2012, 47:825-835.
33. Alhadi S., Tiwari A., Vohra R., Gerona R., Acharya J., Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J. Med. Toxicol. 2013, 9:199-206.
34. Wikstrom M., Thelander G., Dahlgren M., Kronstrand R. An accidental fatal intoxication with methoxetamine. J. Anal. Toxicol. 2013, 37:43-46.
35. Behonick G., Shanks K.G., Firchau D.J., Mathur G., Lynch C.F., Nashelsky M., Jaskierny D.J., Meroueh C. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J. Anal. Toxicol. 2014, 38:559-562.
36. Kacinko S.L., Xu A., Homan J.W., McMullin M.M., Warrington D.M., Logan B.K. Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in Human Whole Blood. J. Anal. Toxicol. 2011, 35:386-393.
37. Teske J., Weller J.P., Fieguth A., Rothamel T., Schulz Y., Troger H.D. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2010, 878:2659-2663.
38. Hutter M., Moosmann B., Kneisel S., Auwarter V. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J. Mass Spectrom. 2013, 48:885-894.
39. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch. Arztebl. Int. 2009, 106:464-467.
40. Dalton V.S., Zavitsanou K. Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. Synapse 2010, 64:845-854.
41. Atwood B.K., Huffman J., Straiker A., Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br. J. Pharmacol. 2010, 160:585-593.
42. Atwood B.K., Lee D., Straiker A., Widlanski T.S., Mackie K. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol. 2011, 659:139-145.
43. Expert Committee on Drug Dependence, 36th ECDD (2014) Agenda Item 4.9. APINACA Critical Review Report. (accessed 12.09.14). https://legal-high-inhaltsstoffe.de/sites/default/files/uploads/akb-48_-_apinaca.pdf.
44. State of Wisconsin Department of Safety & Professional Services, Federal Register, Vol. 78, No. 71. 3/20130425_agenda_SUA3.pdf. (accessed 12.09.14). http://dsps.wi.gov/Documents/Board%20Services/Agenda%20Materials/Controlled%20Substances/2013/20130425_agenda_SUA3.pdf.